Enter Keyword here..

And press enter.

TRIVIRON FORTE

Triviron forte-TRV is an antiviral veterinary product.

Dosage form:  Oral solution, bottle 100 ml

Composition:

1 ml contains 30.0 mg of aRNase (1.5-bis- [N.N- 1- (4- tetradecyl) diazo1-1- abicyclo [2.2.2] octyl] pentane tetrobromide), and excipients: propylene glycol and lactic acid.

Indications for use:

Triviron forte-TRV is used for therapeutic and prophylactic purposes in animals and poultry with infections caused by RNA viruses:

  • poultry – infectious bronchitis of chickens, infectious bursal disease, avian influenza, viral arthritis in poultry, Newcastle disease, pneumovirus in poultry, paramyxoviruses in poultry, infectious encephalomyelitis in poultry, coronavirus enteritis of turkeys, astroviral infections in poultry, hepatitis of ducks, viral hepatitis of turkeys, viral nephritis of turkeys and other infections caused by RNA genomic viruses sensitive to the veterinary product;
  • pigs – rotavirus diarrhea, enteroviral gastroenteritis of piglets, porcine respiratory reproductive syndrome, influenza of piglets, and other infections caused by RNA genomic viruses sensitive to the veterinary product;
  • calves – rotavirus enteritis, coronavirus enteritis, parainfluenza-3, respiratory syncytial infection, and other infections caused by RNA genomic viruses sensitive to the veterinary product.

Method of administration and dosage:

The veterinary product is administered

Pigs:

  • for prophylactic purposes at the dose of 0.05 ml of the veterinary product per 1 kg of body weight. The veterinary product is introduced into the drinking system through a medicator, having previously dissolved it in a volume of water (corresponds to the volume of the medicator’s stock solution), which the pigs can drink within 6-8 hours. The course is 2-10 days.
  • for therapeutic purposes at the dose of 0.1 ml of the veterinary product per 1 kg of body weight. The veterinary product is introduced into the drinking system through a medicator, having previously dissolved it in a volume of water (corresponds to the volume of the medicator’s stock solution), which the pigs can drink within 6-8 hours. The course is 2-10 days.

Poultry:

  • for prophylactic purposes at the dose of 0.00125-0.0025 ml of the veterinary product per 1 kg of body weight. The veterinary product is introduced into the drinking system through a medicator (1-2% input), having previously dissolved it in a volume of water (corresponds to the volume of the medicator’s stock solution), which the poultry can drink within 6-8 hours. The course is 2-10 days.
  • for therapeutic purposes at the dose of 0.0025-0.005 ml of the veterinary product per 1 kg of body weight. The veterinary product is introduced into the drinking system through a medicator (1-2% input), having previously dissolved it in a volume of water (corresponds to the volume of the medicator’s stock solution), which the poultry can drink within 4-6 hours. The course is 2-10 days.

Cattle:

  • for prophylactic purposes at the dose of 0.05 ml of the veterinary product per 1 kg of body weight. Before drinking, the veterinary product must be diluted in drinking water in a ratio of 1: 1000. The course is 2-10 days.
  • for therapeutic purposes at the dose of 0.1 ml of the veterinary product per 1 kg of body weight. Before drinking, the veterinary product must be diluted in drinking water in a ratio of 1: 1000. The course is 2-10 days.

It is forbidden to drink the veterinary product in its pure form to animals and poultry!

When diluting, the veterinary product is added to water in a thin stream (to avoid the formation of a precipitate) with vigorous stirring.

Pharmaceutical properties

The veterinary product has a pronounced effect on RNA-containing viruses of the families Paramyxoviridae, Coronaviridae, Arenaviridae, Retroviridae, Picornaviridae, Birnaviridae, Orthomyxoviridae, etc.

The mechanism of action is based on the damage of RNA viral particles using a low molecular weight artificial ribonuclease. High stability to physical and chemical factors, as well as the small size of artificial RNase in comparison with protein molecules, provide high efficiency of antiviral therapy. The small molecular weight of the compound increases the efficiency of penetration of synthetic ribonuclease into the virus capsid and high chemical and temperature stability provides the possibility of oral administration of the antiviral veterinary product.

The veterinary product is not toxic, no contraindications were found.

The veterinary product, according to the degree of exposure belongs to moderate-hazard substances (hazard class 3 according to GOST 12.1.007-76).